Advertisement

ADVERTISEMENT

Riya Gandhi, MA

QUIZ: Psoriasis and Atopic Dermatitis: Nonsteroidal Topical Therapies
09/15/2024
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein Gold, how do nonsteroidal topical therapies compare to traditional steroid-based treatments for managing psoriasis and AD?a) They are less effective but safer.b) They are as effective as mid-potency steroids and...
1. According to Dr Linda Stein...
09/15/2024
The Dermatologist
Quiz
QUIZ: Topical PDE-4 Inhibitors For Atopic Dermatitis, Seborrheic Dermatitis, and Psoriasis
08/10/2024
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola emphasize for atopic dermatitis?
What strategies did Dr Merola...
08/10/2024
The Dermatologist
Surgical Pearls
Dermatologic Surgery Pearls for Non-Mohs Surgeons
08/07/2024
Consider words of wisdom from your colleagues and share what you have learned with others to help optimize patient care.
Consider words of wisdom from your colleagues and share what you have learned with others to help optimize patient care.
Consider words of wisdom from...
08/07/2024
The Dermatologist
NRS Approved Features
Establishing a Core Domain Set for Rosacea Clinical Trials
08/05/2024
A recent consensus statement addresses the need for standardized outcome measures in clinical trials involving patients with rosacea.
A recent consensus statement addresses the need for standardized outcome measures in clinical trials involving patients with rosacea.
A recent consensus statement...
08/05/2024
The Dermatologist
Clinical Insights
The Risk of Keratinocyte Cancer in Patients With Vitiligo
08/05/2024
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and meta-analysis offers insights into the relationship between vitiligo and nonmelanoma skin cancer, which can be used to enhance patient education.
A recent systematic review and...
08/05/2024
The Dermatologist
Alopecia Areata, blad head
FDA Alerts
Deuruxolitinib FDA Approved for Severe Alopecia Areata in Adults
07/30/2024
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved deuruxolitinib (LEQSELVI) 8 mg tablets for the treatment of adults with severe alopecia areata, a condition affecting approximately 300,000 individuals in the United States.
The FDA has approved...
07/30/2024
The Dermatologist
Atopic dermatitis
FDA Alerts
FDA Approves Roflumilast Cream 0.15% for Treatment of Atopic Dermatitis in Adults and Children Aged 6 and Older
07/09/2024
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug Administration has approved roflumilast cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children aged 6 and older.
The US Food and Drug...
07/09/2024
The Dermatologist
vitiligo
News
Promising Patient Outcomes With Autologous Skin Cell Suspension Transplantation for Vitiligo
06/28/2024
A new study highlights the effectiveness of autologous skin cell suspension transplantation in treating stable vitiligo, showing positive patient-reported outcomes and significant repigmentation improvements.
A new study highlights the effectiveness of autologous skin cell suspension transplantation in treating stable vitiligo, showing positive patient-reported outcomes and significant repigmentation improvements.
A new study highlights the...
06/28/2024
The Dermatologist
vitiligo
News
Evaluating Efficacy of Ritlecitinib With or Without nbUVB in Treating Non-Segmental Vitiligo
06/28/2024
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family kinase inhibitor, has shown promising results in the treatment of non-segmental vitiligo (NSV), according to a recent Phase 2b trial.
Ritlecitinib, a JAK3/TEC family...
06/28/2024
The Dermatologist

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use